Loading…
Werewolf Therapeutics, Inc. is projected to rise to $0.3699 by 2027, a +1% move from its current price of $0.3676. HOWL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.3434 | $0.3674 | $0.3932 | -0.05% |
| Aug 6 | $0.3337 | $0.3673 | $0.4042 | -0.09% |
| Aug 7 | $0.3264 | $0.3671 | $0.4128 | -0.14% |
| Aug 8 | $0.3204 | $0.3669 | $0.4202 | -0.19% |
| Aug 9 | $0.3152 | $0.3667 | $0.4267 | -0.23% |
| Aug 10 | $0.3105 | $0.3666 | $0.4328 | -0.28% |
| Aug 11 | $0.3063 | $0.3664 | $0.4383 | -0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3063 | $0.3664 | $0.4383 | -0.33% |
| Week 2 | $0.2834 | $0.3652 | $0.4706 | -0.66% |
| Week 3 | $0.2668 | $0.364 | $0.4965 | -0.98% |
| Week 4 | $0.2535 | $0.3628 | $0.5193 | -1.31% |
| Week 5 | $0.2422 | $0.3616 | $0.5399 | -1.63% |
| Week 6 | $0.2323 | $0.3604 | $0.5591 | -1.96% |
| Week 7 | $0.2235 | $0.3592 | $0.5773 | -2.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. In addition, it develops JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21 and WTX-518, an activated IL-18 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc.
was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Werewolf Therapeutics, Inc. (HOWL) is a biotechnology company focused on immune-oncology, pursuing a pipeline centered on conditionally activated immunotherapies. The stock currently trades with a market capitalization around $17.16M and holds a rank of 4915.
Its current price is $0.3531 per share, providing a baseline for evaluating the year-by-year forecast range.
A major floor 47.0% below — a decisive break under it would weaken the trend.
The nearest floor, 16.2% below — buyers have tended to step in here.
The nearest ceiling, 36.0% above — a clean break opens room to run.
A major ceiling 182.9% above — clearing it would confirm fresh momentum.
Key HOWL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HOWL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.443 | Sell | $0.4217 | Sell |
| MA 10 | $0.4098 | Sell | $0.4129 | Sell |
| MA 20 | $0.3833 | Sell | $0.3978 | Sell |
| MA 50 | $0.3887 | Sell | $0.4329 | Sell |
| MA 100 | $0.5908 | Sell | $0.538 | Sell |
| MA 200 | $0.7447 | Sell | $0.7383 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.96 | Neutral |
| Stoch RSI (14) | 5.77 | Buy |
| CCI (20) | -51.50 | Neutral |
| Williams %R (14) | -91.88 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 3.82 | Buy |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 8.12 | Buy |
| TRIX (15) | 0.10 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 49.14 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 0.46 | Sell |
| ADX (14) | 20.06 | Sell |
| ATR (14) | 0.03 | Info |
The near-term technical picture is NEUTRAL. The RSI14 sits at 40, suggesting modest momentum with no clear overbought or oversold signal. The 50-day simple moving average is $0.3887, while the 200-day simple moving average is $0.7447. A key support level is $0.308 and a nearby resistance is $0.50.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.308 | $0.3676 | $0.4544 | 0% | Neutral | |
| $0.2695 | $0.3699 | $0.5485 | +1% | Neutral | |
| $0.2028 | $0.296 | $0.4684 | -19% | Bearish | |
| $0.184 | $0.2831 | $0.4706 | -23% | Bearish | |
| $0.18 | $0.2903 | $0.5026 | -21% | Bearish | |
| $0.1932 | $0.3258 | $0.584 | -11% | Neutral | |
| $0.2619 | $0.4606 | $0.8517 | +25% | Bullish | |
| $0.2365 | $0.4331 | $0.8232 | +18% | Neutral | |
| $0.1886 | $0.3594 | $0.7004 | -2% | Neutral | |
| $0.2044 | $0.4048 | $0.8075 | +10% | Neutral | |
| $0.2579 | $0.5731 | $1.26 | +56% | Bullish | |
| $0.3716 | $0.8259 | $1.90 | +125% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.308 | $0.3676 | $0.4538 | +0.00% |
| September 2026 | $0.3078 | $0.3741 | $0.4744 | +1.77% |
| October 2026 | $0.2857 | $0.3522 | $0.4557 | -5.87% |
| November 2026 | $0.2647 | $0.3299 | $0.4339 | -6.31% |
| December 2026 | $0.2703 | $0.3406 | $0.4544 | +3.22% |
Click any year to see its month-by-month HOWL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The HOWL price prediction for 2026 points to an average of $0.3676 (low $0.308, high $0.4544) — a potential gain of 0% on today's $0.3676. A consolidation phase looks the most probable path here.
In 2027, HOWL is projected to trade between $0.2695 and $0.5485, averaging $0.3699 — a potential gain of +1% from today's $0.3676. That is up +1% on the projected 2026 average. Price action looks broadly range-bound.
Werewolf Therapeutics, Inc.'s 2028 outlook centres on $0.296, within a $0.2028 to $0.4684 range. That is -20% versus the projected 2027 average. That marks a -19% change versus current levels. Expect choppier, lower action through this leg of the cycle.
By 2029, HOWL could reach as high as $0.4706, with a base case around $0.2831 and support toward $0.184 — roughly -23% from $0.3676. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect HOWL to range from $0.18 to $0.5026 through 2030. The $0.2903 average target implies a -21% move from current prices. That is up +3% on the projected 2029 average. Expect choppier, lower action through this leg of the cycle.
The HOWL price prediction for 2031 points to an average of $0.3258 (low $0.1932, high $0.584) — a potential decline of -11% on today's $0.3676. Price action looks broadly range-bound.
In 2032, HOWL is projected to trade between $0.2619 and $0.8517, averaging $0.4606 — a potential gain of +25% from today's $0.3676. That is up +41% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Werewolf Therapeutics, Inc.'s 2033 outlook centres on $0.4331, within a $0.2365 to $0.8232 range. That is -6% versus the projected 2032 average. That marks a +18% change versus current levels. Price action looks broadly range-bound.
By 2034, HOWL could reach as high as $0.7004, with a base case around $0.3594 and support toward $0.1886 — roughly -2% from $0.3676. A consolidation phase looks the most probable path here.
Expect HOWL to range from $0.2044 to $0.8075 through 2035. The $0.4048 average target implies a +10% move from current prices. That is up +13% on the projected 2034 average. Price action looks broadly range-bound.
The HOWL price prediction for 2040 points to an average of $0.5731 (low $0.2579, high $1.26) — a potential gain of +56% on today's $0.3676. Buyers look set to stay in control over this stretch.
In 2050, HOWL is projected to trade between $0.3716 and $1.90, averaging $0.8259 — a potential gain of +125% from today's $0.3676. That is up +44% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in HOWL today (≈ 2,720.348205 HOWL) could be worth
$2,246.69
+$1,246.69 (+125%) by 2050 · US Dollar
Based on the average projected HOWL price of $0.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HOWLwould be worth at today's price.
$1,000 invested in HOWL on Jul 31, 2025 (≈ 826.446255 HOWL) would be worth
$303.8
-$696.2 (-69.6%) today · 0.30× · US Dollar
Based on a HOWL entry price of $1.21 vs. today's $0.3676.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.427 | $860.89 | -13.9% |
| 1 month ago | $0.353 | $1,041.36 | +4.1% |
| 3 months ago | $0.723 | $508.44 | -49.2% |
| 6 months ago | $0.679 | $541.38 | -45.9% |
| 1 year ago | $1.21 | $303.8 | -69.6% |
| All time (5.0y) ago | $15.71 | $23.4 | -97.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HOWL forecast.
Our base-case forecast reaches $0.74 around 2050.
Implied market cap at $0.74: $35.96M
The multi-year forecast shows a mixed path with a near-term neutral-to-bearish bias giving way to longer-term upside. In 2026 the avg is $0.3531 with a $0.308–$0.4374 range and 0% ROI, reflecting a flat near-term outlook. The outlook turns more bearish into 2028–2031, with 2030 averaging at $0.2786 and a -21.1% ROI, before a rebound begins in 2032 with an avg of $0.4432 and a 25.5% ROI.
The forecast continues to mix through 2033–2035, but by 2040 the avg reaches $0.5503 with a 55.8% ROI, and by 2050 the avg is $0.7958 with a 125.4% ROI. The 2040 and 2050 periods are marked as BULLISH, while earlier years show distinct Bearish/Neutral signals. The overall path suggests significant upside potential in the long term, but it also carries substantial risk due to notable early-year declines and high volatility (annualized volatility at 100%).
Tap a question to reveal the answer.
In 2030 the avg price is expected to be $0.2786, with a min of $0.1727 and a max of $0.4824. The ROI is -21.1%, and the sentiment is BEARISH.
The forecast shows a mixed outlook: near-term years such as 2026 show an avg price of $0.3531 with 0% ROI and NEUTRAL sentiment, while 2028–2031 are Bearish with negative ROIs. A rebound appears in 2032 (avg $0.4432, ROI 25.5%, Bullish), with stronger upside projected by 2040 ($0.5503 avg, ROI 55.8%, Bullish) and 2050 ($0.7958 avg, ROI 125.4%, Bullish). These are estimates, not guarantees.
Yes, the max forecasts show $1.21 in 2040 and $1.83 in 2050, indicating potential but not guaranteed upside above $1 in the long term.
2026 forecast: min $0.308, avg $0.3531, max $0.4374; ROI 0%; sentiment NEUTRAL.
The current price is $0.3531 per share and the market cap is $17.16M; the rank is 4915.
Werewolf Therapeutics, Inc. Community Discussion
0Share your Werewolf Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.